Filed under: Investing
Allergan (NYSE: AGN) continues to fight off the advances of serial acquirer Valeant (NYSE: VRX) and its partner, hedge fund manager Bill Ackman. Ackman's Pershing Square is Allergan's largest shareholder, and is hoping to convert enough other investors to his side as this deal has gone hostile. Given Allergan's tenous position, rumors continue to swirl that it will make a play for Irish drugmaker Shire (Nasdaq: SHPG). But given the lure of Ireland's low tax rate, Allergan may have to get into a bidding war with AbbVie to pull off its own deal for the ADHD drugmaker.
In this episode of Market Check-Up, the otley Fool's health care focused investing show, analysts David WIlliamson and Michael Douglass, discuss the agressive new posture of Ackman and Valeant, how Allergan is responding, and why its only defense may be to go on the offensive.
Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.
The article #1 Hostile Healthcare Rule: Eat or Be Eaten originally appeared on Fool.com.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
Read | Permalink | Email this | Linking Blogs | Comments